4.5 Review

PML nuclear bodies: from architecture to function

期刊

CURRENT OPINION IN CELL BIOLOGY
卷 52, 期 -, 页码 154-161

出版社

CURRENT BIOLOGY LTD
DOI: 10.1016/j.ceb.2018.03.011

关键词

-

向作者/读者索取更多资源

PML nuclear bodies are nucleated by the PML protein, which polymerizes into spherical shells where it concentrates many unrelated partner proteins. Emerging data has connected PML bodies to post-translational control, notably conjugation by SUMOs. High concentrations of SUMO-bound proteins were proposed to condense into liquid-like droplets and such phase transition may occur within NBs. Many stress pathways modulate NB formation and recent findings have directly implicated PML in oxidative stress response in vivo. PML may also undergo SUMO-dependent ubiquitination/degradation. We highlight recent advances linking PML to partner degradation and other adaptative post-translational modifications in the context of chromatin remodeling, telomere biology, senescence or viral infections.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Yolk sac-derived Pdcd11-positive cells modulate zebrafish microglia differentiation through the NF-κB-Tgfβ1 pathway

Ruimeng Yang, Ming Zhan, Miaomiao Guo, Hao Yuan, Yiqin Wang, Yiyue Zhang, Wenqing Zhang, Saijuan Chen, Hugues de The, Zhu Chen, Jun Zhou, Jun Zhu

Summary: Microglia, the primary immune cells in the central nervous system, are regulated by the cerebral white matter hyperintensities susceptibility gene PDCD11, which plays a crucial role in microglia differentiation during zebrafish development.

CELL DEATH AND DIFFERENTIATION (2021)

Article Immunology

JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

Tracy Dagher, Nabih Maslah, Valerie Edmond, Bruno Cassinat, William Vainchenker, Stephane Giraudier, Florence Pasquier, Emmanuelle Verger, Michiko Niwa-Kawakita, Valerie Lallemand-Breitenbach, Isabelle Plo, Jean-Jacques Kiladjian, Jean-Luc Villeval, Hugues de The

Summary: Research shows that arsenic trioxide (ATO) can significantly enhance IFNα-induced growth suppression of JAK2 (V617F) patient or mouse hematopoietic progenitors, predicting potent clinical efficacy of the IFNα+ATO combination in patients. This combination therapy has the potential to eradicate Myeloproliferative neoplasms by targeting disease-initiating cells.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Review Hematology

Retinoids in hematology: a timely revival?

Marie-Claude Geoffroy, Cecile Esnault, Hugues de The

Summary: Retinoic acid receptors play crucial roles in leukemia, with recent studies showing their significance in non-APL AML and normal hematopoietic differentiation. This sheds light on the potential broader uses of retinoids in the management of hematopoietic tumors.
Article Hematology

Loss of interleukin-10 activates innate immunity to eradicate adult T-cell leukemia-initiating cells

Hiba El Hajj, Rita Hleihel, Marwan El Sabban, Julie Bruneau, Ghazi Zaatari, Morgane Cheminant, Ambroise Marcais, Abdou Akkouche, Hideki Hasegawa, William Hall, Hugues De The, Olivier Hermine, Ali Bazarbachi

Summary: Combining arsenic trioxide and interferon-alpha shows high response rate in chronic ATL patients by shutting down IL-10 expression to eliminate leukemia-initiating cell activity, leading to immune-mediated clearance of leukemic cells.

HAEMATOLOGICA (2021)

Editorial Material Hematology

An exciting RXRA mutant revives interest in retinoids for acute myeloid leukemia

Fang Qiu, Hugues De The

HAEMATOLOGICA (2022)

Article Oncology

Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication

Simona Moretti, Amal Kamal Abdel-Aziz, Elena Ceccacci, Isabella Pallavicini, Fabio Santoro, Hugues de The, Saverio Minucci

Summary: This study demonstrates the importance of simultaneously targeting the plasticity and heterogeneity of cancer cells, specifically leukemia-initiating cells (LICs), in achieving and maintaining complete remission (CR) in acute myeloid leukemia (AML). The combination of certain histone deacetylase (HDAC) inhibitors and all-trans retinoic acid (ATRA) effectively differentiated and targeted LICs, leading to CR in a murine model of AML.

LEUKEMIA (2022)

Article Oncology

Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia

Bryann Pardieu, Justine Pasanisi, Frank Ling, Reinaldo Dal Bello, Justine Penneroux, Angela Su, Romane Joudinaud, Laureen Chat, Hsin Chieh Wu, Matthieu Duchmann, Gaetano Sodaro, Clementine Chauvel, Florence A. Castelli, Loic Vasseur, Kim Pacchiardi, Yannis Belloucif, Marie-Charlotte Laiguillon, Eshwar Meduri, Camille Vaganay, Gabriela Alexe, Jeannig Berrou, Chaima Benaksas, Antoine Forget, Thorsten Braun, Claude Gardin, Emmanuel Raffoux, Emmanuelle Clappier, Lionel Ades, Hugues de The, Francois Fenaille, Brian J. Huntly, Kimberly Stegmaier, Herve Dombret, Nina Fenouille, Camille Lobry, Alexandre Puissant, Raphael Itzykson

Summary: By analyzing multiple AML datasets, we identified SLC7A11 as a potential gene that is essential for AML cell survival. Inhibition of SLC7A11 using genetic and chemical methods reduced the viability and clonogenic capacity of AML cell lines. Sulfasalazine, a drug with xCT inhibitory activity, showed anti-leukemic effects against primary AML samples in vitro. Inhibition of xCT affected multiple metabolic pathways, leading to depletion of glutathione pools and oxidative stress-induced cell death in leukemic cells.

LEUKEMIA (2022)

Review Cell Biology

Sumoylation in Physiology, Pathology and Therapy

Umut Sahin, Hugues de The, Valerie Lallemand-Breitenbach

Summary: Sumoylation is an important post-translational modification that regulates intricate networks within eukaryotic cells. It plays a key role in transcription, nuclear integrity, proliferation, senescence, lineage commitment, and stemness. Additionally, it is involved in infection, immune processes, epigenetic processes, and development. It has been associated with various pathological conditions and has therapeutic potential.
Editorial Material Hematology

In APL, noncoding mutations and SNP converge on WT1

Hsin-Chieh Wu, Hugues de The

Summary: This study investigates the impact of focal noncoding enhancer mutations on MYB binding and WT1 expression in acute promyelocytic leukemia (APL) and reveals their resemblance to a germline single nucleotide polymorphism (SNP) that promotes APL emergence.
Article Multidisciplinary Sciences

Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells

Sarah Tessier, Omar Ferhi, Marie-Claude Geoffroy, Roman Gonzalez-Prieto, Antoine Canat, Samuel Quentin, Marika Pla, Michiko Niwa-Kawakita, Pierre Bercier, Domitille Rerolle, Pierre Therizols, Emmanuelle Fabre, Alfred C. O. Vertegaal, Hugues de The, Valerie Lallemand-Breitenbach

Summary: The authors identify novel PML partners and demonstrate their role in controlling sumoylation and maintaining the transcriptome and transposable element silencing in embryonic stem cells. These findings shed light on the functions of membrane-less organelles and provide new insights into the potential role of PML in embryonic stem cells and cancer.

NATURE COMMUNICATIONS (2022)

Article Biology

Zbtb14 regulates monocyte and macrophage development through inhibiting pu.1 expression in zebrafish

Yun Deng, Haihong Wang, Xiaohui Liu, Hao Yuan, Jin Xu, Hugues de The, Jun Zhou, Zhu Jun, Florent Ginhoux

Summary: This study discovers that the deficiency of ZBTB14 gene leads to an abnormal expansion of monocyte/macrophage population in zebrafish. ZBTB14 functions as a negative regulator of PU.1, and the repression activity of ZBTB14 depends on SUMOylation on a conserved lysine. Furthermore, a mutation can target ZBTB14 protein to autophagic degradation.
Correction Multidisciplinary Sciences

Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells (vol 13, 5726, 2022)

Sarah Tessier, Omar Ferhi, Marie-Claude Geoffroy, Roman Gonzalez-Prieto, Antoine Canat, Samuel Quentin, Marika Pla, Michiko Niwa-Kawakita, Pierre Bercier, Domitille Rerolle, Marilyn Tirard, Pierre Therizols, Emmanuelle Fabre, Alfred C. O. Vertegaal, Hugues de The, Valerie Lallemand-Breitenbach

NATURE COMMUNICATIONS (2023)

Review Immunology

The PML hub: An emerging actor of leukemia therapies

Domitille Rerolle, Hugues de The

Summary: PML nuclear bodies are stress-responsive domains involved in senescence, apoptosis, or metabolism. PML is required for response or even cure of some hematological malignancies. The authors review how PML participates in cancer cell clearance and highlight its druggable aspect.

JOURNAL OF EXPERIMENTAL MEDICINE (2023)

暂无数据